AC Immune KOL Webinar on the Potential Benefits of Vaccines for Alzheimer’s and Parkinson’s Diseases (English only)

• Vaccines can provide safe, long-lasting immunity, and logistical advantages compared to other treatment modalities
• Integrating its precision medicine approach, AC Immune is advancing three clinical-stage vaccines targeting Tau, Abeta and α-synuclein
• Precisely targeted active immunotherapy may enable prevention of pathological pathways before the occurrence of irreversible neuronal damage

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today hosted key opinion leader (KOL) Cynthia A. Lemere, Ph.D., of the Ann Romney Center for Neurologic Diseases at Brigham & Women’s Hospital and Harvard Medical School, Boston, for a webinar focused on vaccines to treat and prevent Alzheimer’s and Parkinson’s diseases.

Detailed Data From the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented at AAIC (English only)

• Crenezumab was safe and well tolerated with no cases of ARIA-E observed during the up to eight-year study
• As previously reported, numerical differences favoring crenezumab over placebo were confirmed across the co-primary, multiple secondary and exploratory endpoints, none statistically significant
• Demographic and baseline biomarker data indicate a confluence of factors which may have caused the study to have lower than expected statistical power
• All mutation carriers may continue to receive crenezumab while the data are further analyzed

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its partners presented the first quantitative data from the Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer’s Disease (ADAD) Colombia Trial during a Focused Topic Session at the Alzheimer’s Association International Conference (AAIC). The study evaluated the potential of the anti-amyloid beta antibody crenezumab to slow or prevent Alzheimer’s disease in cognitively unimpaired people who carry a specific genetic mutation which causes early-onset Alzheimer’s disease.

AC Immune Announces Upcoming Presentations at the Alzheimer’s Association International Conference (English only)

• New data from the API ADAD Study to be presented in AAIC Focused Topic Session
• New Phase 2 results from investigator-sponsored trial of the Tau PET tracer PI-2620 in Alzheimer’s disease
• First-time presentation of innovative biomarker-based translational clinical trial design to evaluate ACI-24.060 in sporadic Alzheimer’s disease and in people with Down syndrome
• Additional data from proof-of-concept clinical study of ACI-12589 PET tracer to detect alpha-synuclein in the brains of living patients

AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced 10 upcoming presentations that will be delivered at the Alzheimer’s Association International Conference (AAIC) in San Diego, California (United States) and online, July 31 – August 4, 2022.

AC Immune Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease (English only)

Crenezumab did not statistically significantly slow or prevent cognitive decline in people
with a specific genetic mutation which causes early-onset Alzheimer’s disease

Numerical differences favouring crenezumab over placebo were observed across the co-primary,
multiple secondary and exploratory endpoints

Initial data will be presented at the Alzheimer’s Association International Conference (AAIC) on
August 2, 2022

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced results from the Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer’s Disease (ADAD) Colombia Trial. The study evaluated the potential of crenezumab, an investigational medicine, to slow or prevent Alzheimer’s disease in cognitively unimpaired people who carry a specific genetic mutation which causes early-onset Alzheimer’s disease.